USTEKINUMAB (Stelara) prior authorization at Highmark
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Highmark requires Interleukin-12 Antagonist prior-authorization documentation for USTEKINUMAB (Stelara): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Highmark reviews USTEKINUMAB (Stelara) prior authorizations against its medical policy for Interleukin-12 Antagonist. Highmark-specific context: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-12 Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Highmark's medical policy URL referenced in the cover letter
Highmark's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Prior auth on biologics
- PA on advanced imaging
- OON balance bills
USTEKINUMAB (Stelara)-specific denial patterns and context
Across payers (not just Highmark), USTEKINUMAB (Stelara)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring TNF-inhibitor first (plaque psoriasis, PsA, Crohn's, UC)
- Site-of-care reduction for IV induction dose
- Biosimilar substitution mid-treatment
- Prior auth missing PASI or HBI documentation
Brand: Stelara. IL-12/23 inhibitor. Loss of exclusivity 2023; FDA-approved biosimilars now include Wezlana (interchangeable), Selarsdi, Pyzchiva, Imuldosa, Otulfi, Steqeyma. Plans aggressively switching to biosimilar in 2025.
Manufacturer patient-assistance program: Janssen CarePath — relevant when a Highmark denial sticks and the patient needs bridge access while appealing.
How Highmark approaches Biologic drugs (mAbs and biosimilars) PAs
Highmark's Biologic drugs (mAbs and biosimilars) reviewer typically anchors USTEKINUMAB (USTEKINUMAB) prior-auth decisions on prior auth on biologics. Pharmacy-benefit review for USTEKINUMAB (USTEKINUMAB) at Highmark is routed through Express Scripts. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Highmark's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Highmark is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Operates BCBS in PA (western), WV, DE, NY (western).
If the PA is denied
Highmark gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.highmark.com/provider) with the same packet plus a peer-reviewed citation supporting USTEKINUMAB (Stelara)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Highmark denial on DenialHelp.
Contact Highmark
- Provider portal: https://www.highmark.com/provider
Frequently asked questions
What documentation does Highmark need for USTEKINUMAB (Stelara) prior auth?
Highmark's typical PA packet for USTEKINUMAB (Stelara): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-12 Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Highmark?
Standard USTEKINUMAB (Stelara) PA decisions at Highmark: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Highmark most often reject USTEKINUMAB (Stelara) for?
Across Highmark's book the common rejection patterns include: Prior auth on biologics; PA on advanced imaging; OON balance bills. For USTEKINUMAB (Stelara) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
What prior failures does Highmark typically require before approving USTEKINUMAB (USTEKINUMAB)?
Highmark's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For USTEKINUMAB (USTEKINUMAB), attach the specific disease-activity instrument Highmark accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Highmark fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with Highmark on USTEKINUMAB (Stelara)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the USTEKINUMAB (Stelara) PA packet
Open ApprovalHelp — generate a USTEKINUMAB (Stelara) prior-auth packet tailored to Highmark's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com